Table 1.
Analysis | Entire cohort (n = 162) | Location analysis (n = 127) | Dominance analysis (n = 110) | |
Age (years) | 60.75±12.91 | 60.86±12.57 | 61.23±12.3 | |
Sex – Males | 122 (75.3%) | 97 (76.4%) | 78 (70.9%) | |
Dominant hand – Right | 120 (74.1%) | 94 (74%) | 110 (100%) | |
Time from injury | 2.78±3.3 | 2.53±2.95 | 2.63±3.18 | |
Num. of HBOT sessions | 40 sessions | 26 (16%) | 22 (17.3%) | 20 (18.2%) |
60 sessions | 136 (84%) | 105 (82.7%) | 90 (81.8%) | |
Type of stroke | Ischemic | 121 (74.69%) | 98 (77.17%) | 85 (77.3%) |
Hemorrhagic | 41 (25.31%) | 29 (22.8%) | 25 (22.7%) | |
Location of injury | Subcortical | 54 (33.3%) | 50 (39.4%) | 36 (32.7%) |
Cortical | 80 (49.4%) | 77 (60.6%) | 58 (52.7%) | |
Atypical &multiple locations | 28 (17.3) | – | 16 (14.5%)* | |
Side of injury | Right | 62 (38.3%) | 53 (41.7%) | 56 (50.9%) |
Left | 87 (53.7%) | 74 (58.3%) | 54 (49.1%) | |
Bilateral | 13 (8%) | – | – | |
Symptoms | Cognitive | 77 (47.5%) | 60 (47.2%) | 49 (44.5%) |
Motor | 132 (81.5%) | 104 (81.9%) | 90(81.8%) | |
Speech | 65 (40.1%) | 54 (42.5%) | 43 (39.1%) | |
CN | 67 (41.4%) | 54 (42.5%) | 46 (41.8%) | |
Ataxia | 57 (35.2%) | 39 (30.7%) | 34 (30.9%) | |
Comorbidities | DM II | 48 (29.6%) | 37 (29.1%) | 28 (25.5%) |
HTN | 107 (66%) | 82 (64.6%) | 74 (67.3%) | |
Dyslipidemia | 107 (66%) | 82 (64.6%) | 75 (68.2%) | |
IHD | 39 (24.1%) | 30 (23.6%) | 28 (25.5%) | |
Previous stroke | 18 (11.1%) | 12 (9.4%) | 10 (9.1%) | |
Smoker | 29 (17.9%) | 23 (18.1%) | 15 (13.6%) | |
Medications | AA | 105 (64.8%) | 78 (61.4%) | 70 (63.6%) |
Statins | 104 (64.2%) | 79 (62.2%) | 72 (65.5%) | |
DM II medications | 37 (22.8%) | 27 (21.3%) | 20 (18.2%) | |
HTN medications | 107 (66%) | 84 (66.1%) | 74 (67.3%) |
Data are expressed as means±standard deviation. *Cerebellum insult only. HBOT – hyperbaric oxygen treatment, CN – cranial nerves, DM II – diabetic mellitus type 2, HTN – hypertension, AA – anti-aggregates.